Earnings Call Summary | Aurora Cannabis(ACB.US) Q4 2024 Earnings Conference
Earnings Call Summary | Aurora Cannabis(ACB.US) Q4 2024 Earnings Conference
The following is a summary of the Aurora Cannabis Inc. (ACB) Q4 2024 Earnings Call Transcript:
以下是極光大麻公司（ACB）2024財年第四季度業績會成績單摘要：
Financial Performance:
金融業績：
Net revenue for Aurora Cannabis increased by 21% on a trailing 12-month basis.
Adjusted gross margin was reported at 49%.
Positive adjusted EBITDA was achieved in each of the four fiscal quarters, marking the first time Aurora reported annual positive adjusted EBITDA.
Cash balance ended the year at approximately $180 million.
極光大麻公司淨營業收入在過去12個月內上漲了21%。
調整後的毛利率報告爲49%。
在四個財季中實現了正面調整後的利潤在稅前及折舊前利潤（EBITDA），這標誌着極光大麻公司首次報告年度正面調整後的EBITDA。
年末現金結餘約爲1.8億美元。
Business Progress:
業務進展：
Significant growth in the global medical cannabis business, accounting for 68% of total revenue and 90% of adjusted gross profit for the quarter.
Acquired remaining 90% equity interest in MedReleaf Australia, strengthening position in Australia's medical cannabis market.
Introduced new products including premium dried flower products and resin cartridges.
Entered New Zealand and Switzerland markets, expanding global reach.
Focused on medical cannabis, leveraging experience and EUGMP certified facilities to target internationally regulated markets.
全球醫用大麻業務增長迅速，季度總收入的68%以及調整後的毛利潤的90%歸於該業務板塊。
收購了MedReleaf Australia剩餘90%的股權，鞏固了在澳洲醫用大麻市場的地位。
推出了高端的乾花產品和樹脂筆等新產品。
進入了新西蘭和瑞士市場，擴大了全球市場。
專注於醫用大麻，利用經驗和EUGMP認證的設施來瞄準國際監管市場。
Opportunities:
機會：
Medical cannabis sector showing robust growth, with only about 1% of the Canadian adult population currently using medical cannabis, indicating significant potential for market expansion.
Regulatory changes, like those in Germany, which recently descheduled cannabis, could increase patient access and market size, allowing Aurora to capitalize on these developments.
醫用大麻行業呈現出強勁增長，加拿大成年人目前只有約1%使用醫用大麻，這意味着市場擴張的巨大潛力。
類似德國最近取消對大麻藥品的禁制措施等監管變化可能會增加患者准入和市場規模，從而使極光大麻公司受益。
Risks:
風險：
Decline in consumer cannabis revenue due to strategic shift towards higher-margin medical cannabis.
因戰略轉向高利潤醫用大麻，消費者大麻收入下降。
More details: Aurora Cannabis IR
更多詳情：極光大麻IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。